Hamilton Wealth LLC Acquires New Stake in Regeneron Pharmaceuticals, Inc. $REGN

Hamilton Wealth LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 12,581 shares of the biopharmaceutical company’s stock, valued at approximately $7,074,000. Regeneron Pharmaceuticals comprises about 1.5% of Hamilton Wealth LLC’s holdings, making the stock its 21st biggest position.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Salomon & Ludwin LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $31,000. Caitlin John LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $34,000. Traub Capital Management LLC acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $38,000. Finally, E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 87.5% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.1%

REGN opened at $745.77 on Monday. The firm has a market cap of $78.84 billion, a P/E ratio of 17.94, a PEG ratio of 2.00 and a beta of 0.40. The business’s fifty day simple moving average is $769.73 and its 200 day simple moving average is $695.68. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the firm earned $12.07 EPS. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Wall Street Zen cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Royal Bank Of Canada raised their target price on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a report on Monday, March 2nd. Cantor Fitzgerald upped their price target on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Finally, JPMorgan Chase & Co. raised their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Insiders Place Their Bets

In other news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.